Program

Program subject to change

Day 1 – Wednesday, 19 September 2018
8:00-20:00
Registration
8:30-12:00
ISPOR HTA Roundtable - MEA
 

By Invitation Only

10:00-12:00
ISPOR Arabic Network Meeting
 

By Invitation Only

12:00-20:00
Exhibition Open
13:00-14:00
Educational Symposium
14:15-16:15
Educational seminar: Introduction to Health Economics
 

The session will introduce you to health economics as a sub-discipline of economics and its relevance to decision making in the healthcare sector.

The first part of the session will provide an overview of the principal concepts and theoretical foundations of health economics and how these help us to understand how healthcare markets work; the various market failures that can arise in healthcare; and the role of governments in regulating, funding and providing healthcare.

The second part of the session will introduce the methods and use of economic evaluation of healthcare, and how these can be used to assess value for money in decisions affecting the allocation of health care budgets.

 

Lecturer:
Nancy J. Devlin, BA Hons, PhD
Director of Research, Office of Health Economics
London, United Kingdom
Bio

16:15-16:45
Coffee break
16:45-18:45
Educational Seminar: Introduction to HTA
 

This session will introduce health technology assessment (HTA), the context of how it fits into healthcare decision-making and its relevance to evidence based health policy and the implementation of efficient healthcare.

After providing an overview of the HTA journey (including horizon scanning), the key models and components of HTA, including health economics, different approaches of HTA implementation will be presented, including the initiative of the European Union for HTA collaboration.

The session will explore which HTA deliverables are more transferable across countries to reduce duplication of efforts.

Finally the session will introduce the concept of extended value framework for health technologies, and how the transparency and consistency of decisions may be improved by applying multi-criteria decision analysis (MCDA) based on different domains of HTA and the value framework.

 

Lecturers:

Zoltán Kaló
Zoltán Kaló, PhD
Professor of Health Economics, Department of Health Policy and Economics
Institute of Economics, Faculty of Social Sciences, Eötvös Loránd University (ELTE)
Budapest, Hungary
Bio
Panos Kanavos
Panos Kanavos
Associate Professor in International Health Policy in the Department of Health Policy at London School of Economics and Political Science
Deputy Director at LSE Health and Program Director of the Medical Technology Research Group (MTRG)
London, United Kingdom
Bio
Finn B. Kristensen
Finn Børlum Kristensen, MD, PhD
Professor in Health Services Research and HTA at Department of Public Health
Research Unit of User Perspectives, University of Southern Denmark
Copenhagen, Denmark
Bio
18:45-20:00
Welcome Reception
 

In cooperation with The Department of Tourism and Commerce Marketing (DTCM) – Dubai Business Events

Day 2 – Thursday, 20 September 2018
6:30-17:30
Exhibition Open
6:30-17:30
Registration
7:00-8:00
Sponsored symposium
8:15-9:15
Sponsored symposium
8:00-9:30
Welcome refreshments
9:30-10:00
Welcome and Opening remarks
 
Nancy Berg

Speaker:
Nancy S. Berg
Chief Executive Officer and Executive Director
ISPOR—The Professional Society for Health Economics and Outcomes Research
Lawrenceville, NJ, USA
Bio

 

Keynote Address

Amin Al Amiri

Speaker:
Dr. Amin Al Amiri
Undersecretary Asst. for Health Policies and Licensing
Ministry of Health and Prevention, United Arab Emirates
Bio

10:00-11:00
Role of HEOR in Decision Making: Global Knowledge for Local Application
 

This session will discuss the role which health economics and outcomes research plays in healthcare decisions, drawing on the experience of the United Kingdom, USA, United Arab Emirates and Egypt.

 

Role of HEOR in Decisions – a UK Perspective

 

Speaker:
Nancy J. Devlin, BA Hons, PhD
Director of Research, Office of Health Economics
London, United Kingdom
Bio

 

US Value Frameworks and Implications for Health Outcomes Research

 

Speaker:
Dan Malone, RPh, PhD, FAMCP
Professor of Pharmacy, College of Pharmacy
University of Arizona, Tucson, USA
Bio

 

Presentations from a MENA Region Perspective

 
Ola Ghaleb Al Ahdab, PhD

Speaker:
Ola Ghaleb Al Ahdab, PhD
Pharmaceutical Advisor, Drug Department & CPD-Pharma Founder & Program Manager
Ministry of Health and Prevention
United Arab Emirates
Bio

Sherif Abaza, MBA

Speaker:
Sherif Abaza, MBA
General Manager, Syreon Middle East
Egypt
Bio

11:00-11:15
Coffee break
11:15-12:30
Improving Access to Innovative Health Technologies
 

Healthcare policy makers across the region are currently exploring options to establish HTA in their country. Frequently, opportunities and limitations of HTA to effectively address decision-making objectives and constraints are not well characterized or understood.

Process of improving patient access to innovative health technologies can benefit from alignment of realistic expectations towards HTA and evidence-informed decision- making.

During this session the following aspects, among others, will be addressed form the multi-stakeholder perspective:

  • highlight the need to systematically align the expectations of patients, their caregivers and wider society towards collectively funded healthcare systems in light of available healthcare resources by means of evidence-informed decision processes
  • stress the complementary need for healthcare systems to introduce aligned incentives for healthcare decision makers, providers, and patients to continuously improve the cost-effectiveness of innovative healthcare technologies over time
  • share learnings and best practice with a specific focus on the opportunities and limitations of active stakeholder engagement in HTA (patients, providers and industry)
 
Ansgar Hebborn, PhD

Moderator:
Ansgar Hebborn, PhD
Head, HTA & Payment Policy, Global Pricing & Market Access (GPMA)
F. Hoffmann-La Roche AG, Basel, Switzerland
Bio

 

MENA Region panelists:

 
Adham Ismail
Adham Ismail, MSc, MBA, PhD
Team Leader, Essential Medicines and Technologies & Regional Advisor
Health Technology and Biomedical Devices
Department of Health System Development, WHO – EMRO Egypt
Bio
Saad M. Jaddoua
Saad M. Jaddoua, Bs. Pharm. RPH.
Chairman, Department Of Pharmacy
King Hussein Cancer Center
Amman, Jordan
Bio
Ahmed Al-jedai
Ahmed Al-jedai, Pharm.D., M.B.A., BCPS, FCCP, FAST
Pharmaceutical Care Division|
Professor, Alfaisal University, College of Medicine
Consultant Clinical Pharmacist, Solid Organ Transplant
King Faisal Specialist Hospital & Research Centre
Riyadh, Kingdom of Saudi Arabia
Bio
Fatima Ali Al Breiki
Fatima Ali Al Breiki
Group Pharmaceuticals Director
Corporate Support Services
Abu Dhabi Health Services Company – SEHA
Abu Dhabi, United Arab Emirates
Bio
12:30-13:45
Lunch
13:45-15:00
Pricing and Reimbursement: Issues and Challenges
 

The objective of the session will be to highlight and discuss a number of significant challenges in pricing and reimbursement facing the countries in the region, in their pursuit to contain costs, improve efficient allocation of resources and enable faster access to new therapies. Specifically, the panel will discuss the following themes:

  • the extent to which external reference pricing constitutes efficient regulation to promote efficiency and aligns public expectations with economic reality;
  • the challenges and opportunities for reimbursement systems for pharmaceuticals in the Middle East and North Africa and ways to improve coverage;
  • a review of the value assessment criteria for new therapies and how they are used in different settings;
  • how innovative payment schemes and risk sharing, including coverage with evidence development, can be incorporated in decision-making processes in the region and what does the European / international experience suggest about their use.
 
Panos Kanavos

Moderator:
Panos Kanavos
Associate Professor in International Health Policy in the Department of Health Policy at London School of Economics and Political Science
Deputy Director at LSE Health and Program Director of the Medical Technology Research Group (MTRG)
London, United Kingdom
Bio

 

MENA Region panelists:

 
Kasem Akhras

Kasem Akhras
Senior Director – Public Affairs
Middle East & North Africa Region, Novartis
United Arab Emirates
Bio

Gihan Hamdy Elsisi, MSc, PhD

Gihan Hamdy Elsisi Msc, PhD
Head of Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs
Ministry Of Health
Egypt
Bio

Abdulaziz H. Al-Saggabi, BSc, MSc, PharmD

Abdulaziz H. Al-Saggabi, BSc, MSc, PharmD
Director, Drug Policy & Economics Center
Ministry of National Guard Health Affairs
Saudi Arabia
Bio

Shadi Saleh, PhD

Shadi Saleh, PhD
Associate Vice President for Health Affairs and Professor of Health Systems and Financing,
American University of Beirut
Lebanon
Bio

15:00-15:15
Coffee break
15:15-16:45
HTA Implementation Roadmap in the Middle East and North Africa
 

The costs associated with opportunities forgone in inappropriate health policy decisions is especially high in countries with economic recession. Application of health technology assessment (HTA) informing policy decisions (eg, pricing, reimbursement) can improve the allocative efficiency of scarce resources contributing to optimal distribution of goods and services while taking into account patients’ and consumers’ preferences. Development and implementation of an HTA system could benefit from the knowledge transfer from other countries where such a system has been established thus, eg, avoiding the mistakes the others made. At the same time, realistic assessment of the specific economic and governance situations in the countries of the MENA region must be considered when developing an appropriate roadmap for HTA implementation responsive to the local needs.

This session aims to describe the main HTA implementation scenarios in the MENA countries and summarize the most important questions related to capacity building, financing HTA, process and organizational structure for HTA, standardization of HTA methodology, use of local data, scope of mandatory HTA, and decision criteria. The panel session – including introductory presentation and roundtable discussion – will help clarifying (1) long-term objectives and (2) immediate possible steps of HTA implementation in the MENA region.

 
Zoltán Kaló

Moderator:
Zoltán Kaló, PhD
Professor of Health Economics, Department of Health Policy and Economics
Institute of Economics, Faculty of Social Sciences, Eötvös Loránd University (ELTE)
Budapest, Hungary
Bio

 
Finn B. Kristensen

Speaker:
Finn Børlum Kristensen, MD, PhD
Professor in Health Services Research and HTA at Department of Public Health
Research Unit of User Perspectives, University of Southern Denmark
Copenhagen, Denmark
Bio

 

MENA Region speakers:

 
Maryam Alowayesh, MSc, PhD

Maryam Alowayesh, MSc, PhD
Assistant Professor
School of Pharmacy, Kuwait University
Kuwait
Bio

Mohsen George, MD

Mohsen George, MD
Vice President, Health Insurance Organization
First Undersecretary, Ministry of Health
Egypt
Bio

Abeer A. Al-Rabayah, BSc, MBA, MSc

Abeer A. Al-Rabayah, BSc, MBA, MSc
Head, Center for Drug Policy & Technology Assessment (CDPTA)
King Hussein Cancer Center
Amman, Jordan
Bio

Rita Karam, PharmD, PhD

Rita Karam, PharmD, PhD
Director, Quality Assurance of Pharmaceutical Products
Ministry of Health
Beirut, Lebanon
Bio

Mouna Jameleddine, PharmD, MSc

Mouna Jameleddine, PharmD, MSc
Head, Health Technology Assessment Department
National Instance for Assessment & Accreditation in Healthcare – INASanté
Tunis, Tunisia

Ahmad Nadeer Fasseeh, BPharm, MBA

Session Facilitator:
Ahmad Nadeer Fasseeh, BPharm, MBA
Doctoral School of Sociology at Eötvös Loránd University (ELTE)
Budapest, Hungary

16:45-17:00
Conclusions and close of the conference

 

Exhibitor Directory

Sponsoring Organizations

 

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.